Dynamic BH3 Profiling to Guide Therapy for Relapsed AML
Official title: Prospective Dynamic BH3 Profiling for Clinical Use in Relapsed or Refractory AML
Funded at Dana-Farber Cancer Inst · NIH-11449514 · Data updated 2026-11-12
A test called dynamic BH3 profiling will help doctors choose the best treatment for people whose AML has come back or not responded to initial therapy.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $388,616 |
| NIH project number | 1R37CA304011-01A1 |
| Project ID | NIH-11449514 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with relapsed or refractory AML who are candidates for venetoclax-containing or other targeted/chemotherapy regimens.
✕Less likely to help
Patients whose leukemia biology does not align with the assay’s predictive capabilities or who are not treated with venetoclax or similar agents.
What this research studies
This project uses a quick ex vivo test on leukemia cells to see how these cells respond to venetoclax and other treatments. The goal is to predict which therapies are most likely to work for an individual patient with relapsed or refractory AML. By identifying effective drug partners, it aims to tailor treatment choices and improve chances of remission. The work builds on prior data showing the assay can forecast in vivo responses, and it plans to test this prospectively in clinical settings.
Why it matters
Potential benefit: If successful, patients with relapsed AML could receive more effective, personalized treatment plans.
How similar studies have gone: Previous studies suggest dynamic BH3 profiling can predict treatment response, but prospective clinical validation is needed.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Garcia, Jacqueline Suen — Dana-Farber Cancer Inst
- Study coordinator: Garcia, Jacqueline Suen
Related research
Other NIH-funded projects on the same topics.
-
Helping young people with cancer understand their genetic risks
This study is creating a special program to help teenagers and young adults with hereditary cancer risks learn about their health and make smart choices, while also supporting their families along the way.
-
Core administrative hub for a multifaceted cancer center program
A large, international cancer research program at Dana-Farber aims to advance a curative strategy for multiple myeloma by coordinating translational research, clinical trials, and data analysis.
-
Automated, interactive lab tool to define radiation targets in cancer care
Aims to make it easier and safer to outline the area to treat in radiation therapy for cancers by using smart software and a patient-friendly interface.
-
Cancer Atlas Network data hub to share big cancer data
A national project helps researchers store, harmonize, and share large cancer data collections so doctors and scientists can learn from many patients.
-
Bridge-building cancer research partnership for education, outreach, and science
A joint effort between UMass Boston and Harvard Cancer Consortium to accelerate cancer research and education by connecting lower-resourced institutions with a leading cancer center.
-
NexTGen: Next-Generation T cell therapy for childhood cancers
A charity-friendly overview: researchers at Dana-Farber are developing advanced engineered T-cell therapies to treat pediatric solid cancers like brain tumors and sarcomas.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.